A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs TSR 033 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms CITRINO
  • Sponsors TESARO
  • Most Recent Events

    • 10 Aug 2017 According to an AnaptysBio media release, TESARO received clearance of an Investigational New Drug application (IND) for TSR-033.
    • 09 Aug 2017 According to TESARO media release, , status changed from planning to recruiting.
    • 01 May 2017 According to TESARO media release, the compnay has submitted an Investigational New Drug (IND) Application for TSR-033 to the U.S. Food and Drug Administration and plans to initiate this trial in mid-2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top